A problem with dengue virus vaccine
…the virus. The results of a phase 3 clinical trial indicated that immunization protected not only against primary infection, but also against severe disease. Dengvaxia was licensed based on data…
…the virus. The results of a phase 3 clinical trial indicated that immunization protected not only against primary infection, but also against severe disease. Dengvaxia was licensed based on data…
…are open label trials relying on subjective outcomes. Trials with this design are fraught with bias, which is why they are no longer considered as reliable evidence for making decisions…
…escalated development and sent vaccine to NIAID to begin the process of initiating a phase I trial to test the safety and immunogenicity of the vaccine. The trial is projected…
…small clinical trial has revealed it to be effective in reducing viral loads in COVID-19 patients. Entry of enveloped viruses into cells requires fusion of viral and cell membranes to…
…through human phase I trials, and stockpiled for the next pandemic. But there was no money to support such work – neither in the halls of big Pharma or forthcoming…
…prevent microbial contamination. The results of several large epidemiological studies found no connection between autism and thimerosal. Nevertheless, the preservative was removed from most childhood vaccines – probably an error,…